KalVista Pharmaceuticals Income Statement (2014-2025) | KALV

1Y3Y5Y7Y10YAll
Download Data
Income Statement Mar2014 Jun2014 Sep2014 Dec2014 Mar2015 Jun2015 Sep2015 Dec2015 Mar2016 Jul2016 Oct2016 Jan2017 Apr2017 Jul2017 Oct2017 Jan2018 Apr2018 Jul2018 Oct2018 Jan2019 Apr2019 Jul2019 Oct2019 Jan2020 Apr2020 Jul2020 Oct2020 Jan2021 Jul2023 Oct2023 Jan2024 Apr2024 Jul2024 Oct2024 Dec2024 Apr2025
Revenue & cost
Revenue 0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.97M0.20M0.25M0.11M0.10M1.13M2.33M4.84M3.72M5.59M3.89M2.93M3.37M3.92M1.58M3.82M
Operating items
Research & Development 1.43M1.75M2.09M3.90M4.50M3.53M4.26M3.53M3.40M2.93M3.34M3.00M3.48M4.36M4.55M5.85M8.36M7.88M7.65M11.14M9.69M9.79M11.23M9.48M22.52M25.25M26.61M16.61M
Selling, General & Administrative 0.44M0.69M1.49M1.01M1.17M1.37M1.32M1.54M2.70M1.29M5.03M2.20M2.07M2.70M2.13M1.96M2.37M2.61M2.90M3.05M3.25M3.42M3.07M3.30M10.63M23.21M17.60M29.20M
Other Operating Expenses 3.83M-0.00M1.46M0.00M-9.56M
Operating Expenses 1.86M2.44M3.58M3.83M4.91M5.67M4.91M5.58M6.54M6.09M4.22M8.37M5.20M5.55M7.06M6.68M7.81M10.73M10.48M10.55M14.19M12.93M13.21M14.30M12.78M33.15M48.45M44.22M45.81M
Operating Income -1.86M-2.44M-3.57M-4.90M-5.67M-4.90M-5.57M-6.53M-5.12M-4.03M-8.12M-5.09M-5.45M-5.94M-4.35M-2.97M-7.01M-4.89M-6.66M-11.26M-9.56M-9.29M-12.72M-8.96M-33.15M-48.45M-44.22M-45.81M
EBIT -1.86M-2.44M-3.57M-4.90M-5.67M-4.90M-5.57M-6.53M-5.12M-4.03M-8.12M-5.09M-5.45M-5.94M-4.35M-2.97M-7.01M-4.89M-6.66M-11.26M-9.56M-9.29M-12.72M-8.96M-33.15M-48.45M-44.22M-45.81M
Non-operating items
Interest & Investment Income -0.08M0.00M0.00M0.55M0.00M0.00M0.00M0.01M0.01M0.01M0.01M0.01M0.00M0.00M0.01M0.07M0.09M0.20M0.72M0.38M0.59M0.51M0.37M0.36M0.68M1.51M1.69M1.36M
Other Non Operating Income -0.08M-0.07M0.55M-3.18M0.00M-0.00M1.39M0.37M0.66M0.82M0.56M0.87M-1.89M1.99M1.82M1.62M1.73M2.51M2.09M2.32M2.92M2.50M2.32M2.43M1.57M2.12M
Non Operating Income -0.16M-0.20M-0.07M0.55M-0.00M0.00M-4.36M-0.00M1.68M0.73M0.66M0.88M0.56M0.95M0.98M1.99M1.98M1.62M2.70M2.86M2.23M3.39M3.43M2.25M4.12M3.81M3.77M3.54M
Net income details
EBT -2.02M-2.52M-3.92M-5.18M-5.83M-4.99M-5.66M-6.60M-5.11M-4.01M-8.11M-5.08M-5.45M-5.94M-4.33M-2.90M-6.92M-4.69M-5.94M-10.88M-8.97M-8.78M-12.35M-8.59M-29.03M-44.65M-40.44M-42.27M
Profit After Tax -2.02M-2.63M-4.00M-4.71M-5.18M-9.01M-4.99M-5.66M-6.61M-3.44M-3.30M-7.64M-4.20M-4.93M-4.99M-5.23M-0.66M-5.03M-3.30M-3.96M-8.53M-7.34M-5.90M-9.29M-6.58M-29.03M-44.65M-40.44M-42.27M
Income from Continuing Operations -2.02M-2.52M-3.92M-5.18M-5.83M-4.99M-5.66M-6.60M-5.11M-4.01M-8.11M-5.08M-5.45M-5.94M-4.33M-2.90M-6.92M-4.69M-5.94M-10.88M-8.97M-8.78M-12.35M-8.59M-29.03M-44.65M-40.44M-42.27M
Consolidated Net Income -2.02M-2.52M-3.92M-5.18M-5.83M-4.99M-5.66M-6.60M-5.11M-4.01M-8.11M-5.08M-5.45M-5.94M-4.33M-2.90M-6.92M-4.69M-5.94M-10.88M-8.97M-8.78M-12.35M-8.59M-29.03M-44.65M-40.44M-42.27M
Income towards Parent Company -2.02M-2.52M-3.92M-5.18M-5.83M-4.99M-5.66M-6.60M-5.11M-4.01M-8.11M-5.08M-5.45M-5.94M-4.33M-2.90M-6.92M-4.69M-5.94M-10.88M-8.97M-8.78M-12.35M-8.59M-29.03M-44.65M-40.44M-42.27M
Net Income towards Common Stockholders -2.02M-2.52M-3.92M-5.18M-5.83M-4.99M-5.66M-6.60M-4.47M-4.24M-7.86M-4.20M-4.93M-4.99M-5.23M-0.66M-6.92M-4.69M-5.94M-10.88M-8.97M-8.78M-12.35M-8.59M-29.03M-44.65M-40.44M-42.27M
Additional items
EPS (Basic) -4.39-4.26-5.89-6.82-7.38-0.40-0.19-0.21-0.25-6.66-5.98-1.03-0.43-0.51-0.50-0.49-0.06-0.47-0.22-0.23-0.49-0.42-0.33-0.52-0.37-0.84-1.07-0.87-0.91
EPS (Weighted Average and Diluted) -0.48-0.84-1.07-0.87-0.91
Shares Outstanding (Weighted Average) 1.66M1.87M1.88M1.88M1.88M1.88M1.88M1.88M9.71M9.71M9.71M9.71M10.78M10.80M10.80M17.18M17.23M17.25M17.39M17.82M17.85M17.85M17.85M17.91M17.94M34.23M34.40M34.56M42.19M42.74M49.42M49.42M49.72M
Shares Outstanding (Diluted Average) 17.75M34.41M34.57M34.72M36.79M46.23M46.70M
EBITDA -1.86M-2.44M-3.57M-4.90M-5.67M-4.90M-5.57M-6.53M0.89M-1.97M-7.48M-3.94M-4.81M-5.03M-2.80M-1.63M-6.35M-3.11M-3.82M-8.35M-7.40M-5.38M-9.21M-7.08M-28.86M-44.84M-39.82M-42.10M
Interest Expenses 0.08M0.08M0.36M0.56M0.84M0.17M0.10M0.09M0.09M